text_1: Crohn’s patients respond to J&J’s Stelara in study.
text_2: Without evaluating the evidence, it becomes one of those classic stories of a new therapy spun in the most favorable light possible based on a limited presentation at a medical meeting. Crohn’s disease is a terrible condition and more treatment options are needed. Thus this new research is welcome and we hope ustekinumab proves successful in phase 3 research. But in order to understand what the current study means, readers must know that data presented at conferences are preliminary and how independent experts assess it.